发布求助
文献互助 智能选刊 最新文献

Clinical Advances in Hematology & Oncology最新文献

筛选
英文 中文
Selecting patients with metastatic hormone-sensitive prostate cancer for combination therapy. 选择对激素敏感的转移性前列腺癌患者进行联合治疗。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Anthony P Lam
{"title":"Selecting patients with metastatic hormone-sensitive prostate cancer for combination therapy.","authors":"Anthony P Lam","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL? 泊纳替尼是否应作为Ph+ ALL的标准酪氨酸激酶抑制剂？
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Elias Jabbour
{"title":"Should ponatinib be the standard-of-care tyrosine kinase inhibitor in Ph+ ALL?","authors":"Elias Jabbour","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Targeted therapy in prostate cancer: beyond PSMA. 前列腺癌的靶向治疗：超越 PSMA。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Michael J Morris
{"title":"Targeted therapy in prostate cancer: beyond PSMA.","authors":"Michael J Morris","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Managing patients with metastatic hormone-sensitive prostate cancer: a shared-care approach to combination therapy. 转移性激素敏感性前列腺癌患者的管理：联合疗法的共同护理方法。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Anthony P Lam, David J Cahn, Manojkumar Bupathi
{"title":"Managing patients with metastatic hormone-sensitive prostate cancer: a shared-care approach to combination therapy.","authors":"Anthony P Lam, David J Cahn, Manojkumar Bupathi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The treatment landscape for metastatic hormone-sensitive prostate cancer has evolved significantly over the past decade. Androgen deprivation therapy (ADT) was once the first-line standard of care, but the introduction of combination therapies, including ADT with chemotherapy or antiandrogens, has markedly improved overall survival. Multiple studies have demonstrated that doublet therapies offer substantial survival benefits. More recently, triplet therapy--combining ADT with docetaxel and second-generation antiandrogens--has further improved patient outcomes. Selecting the appropriate combination therapy requires balancing efficacy and toxicity, particularly for older patients or those with comorbidities. Optimal management of these patients demands a multidisciplinary approach that integrates expertise from oncologists, urologists, and other specialists. The shared-care model enhances patient outcomes by facilitating collaboration and optimizing individualized treatment plans. Strengthening communication between oncologists and urologists, particularly regarding the implementation of triplet therapies, is critical for improving patient care.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of unresectable and resectable stage IV colorectal cancer. 治疗无法切除和可切除的 IV 期结直肠癌。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Julia L Bachler, Gazala N Khan, Ira S Wollner, Philip A Philip
{"title":"Treatment of unresectable and resectable stage IV colorectal cancer.","authors":"Julia L Bachler, Gazala N Khan, Ira S Wollner, Philip A Philip","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Colorectal cancer is the third most commonly diagnosed cancer in the United States. Approximately 20% of patients have metastatic disease at diagnosis, and a proportion of patients with initially localized disease will experience systemic disease recurrence. In the era of molecular subtyping, we have an increasing number of systemic therapies and the opportunity to individualize the treatment of patients with advanced disease. Nonetheless, the 5-year overall survival rate remains unsatisfactory for this patient population. Most patients will be treated with palliative cytotoxic therapy, often with an added monoclonal antibody. Molecular subtyping allows patients to receive targeted therapies upon further lines of therapy. A small portion of patients will have oligometastases that may be amenable to resection or locoregional therapies to help improve outcomes with systemic therapy. Here, we review the current treatment of patients with unresectable and resectable stage IV colorectal cancer, with a focus on pharmacologic therapies.</p>","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607121","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does combination menopausal hormone therapy increase the risk of breast cancer? 更年期激素联合疗法会增加罹患乳腺癌的风险吗？
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Wendy Y Chen, Avrum Bluming
{"title":"Does combination menopausal hormone therapy increase the risk of breast cancer?","authors":"Wendy Y Chen, Avrum Bluming","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606977","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tackling the cancer drug shortage. 解决抗癌药物短缺问题。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Marta E Wosinska, Erin R Fox
{"title":"Tackling the cancer drug shortage.","authors":"Marta E Wosinska, Erin R Fox","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recombinant ADAMTS13 concentrate in thrombotic thrombocytopenic purpura. 重组 ADAMTS13 浓缩液在血栓性血小板减少性紫癜中的应用。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Spero R Cataland
{"title":"Recombinant ADAMTS13 concentrate in thrombotic thrombocytopenic purpura.","authors":"Spero R Cataland","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142606904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A shared-care approach to the management of patients with mHSPC: the urology perspective. 管理 mHSPC 患者的共同护理方法：泌尿外科的视角。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
David J Cahn
{"title":"A shared-care approach to the management of patients with mHSPC: the urology perspective.","authors":"David J Cahn","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The importance of the shared-care approach when triplet therapy is selected in mHSPC: Q&A. mHSPC患者选择三联疗法时共同护理方法的重要性：问与答。
IF 1.1
Clinical Advances in Hematology & Oncology Pub Date : 2024-11-01
Anthony P Lam, David J Cahn, Manojkumar Bupathi
{"title":"The importance of the shared-care approach when triplet therapy is selected in mHSPC: Q&A.","authors":"Anthony P Lam, David J Cahn, Manojkumar Bupathi","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":51585,"journal":{"name":"Clinical Advances in Hematology & Oncology","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142607281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信